Amarantus Bioscience Holdings Inc (AMBS)

[betelgeuse]

http://www.nj.com/business/index.ssf/2013/05/novartis_looks_to_become_playe.html


"Novartis is pursuing alternatives including licensing agreements. This remains high on our radar, with high unmet medical need. It’s an area that we haven’t given up on."

Since the Exelon patch works for Parkinson's patients as well, AMBS's LymPro/NuroPro diagnostic Kits could have a game-changing role to play for Novartis. From both science and investment point of views, Novartis's efforts to find the underlying causes of Alz and PD could be served well by AMBS's research.

Please remember that the pps is not the important thing right now. What matters is how many shares you have, because each of those will be ~$10 by Dec 2014, as per my calculations.